Recently, more than 30 small molecules and eight monoclonal antibodies that modulate kinase signaling have been approved for the treatment of several pathological conditions, including cancer, idiopathic pulmonary fibrosis, and rheumatoid arthritis. first kinase inhibitor developed for AZD6738 supplier clinical use and began the era of molecularly targeted therapy. BCR-ABL is one of the main… Continue reading Recently, more than 30 small molecules and eight monoclonal antibodies that